ATE253122T1 - Vektor für polynukleotidimpfstoffe - Google Patents

Vektor für polynukleotidimpfstoffe

Info

Publication number
ATE253122T1
ATE253122T1 AT97937243T AT97937243T ATE253122T1 AT E253122 T1 ATE253122 T1 AT E253122T1 AT 97937243 T AT97937243 T AT 97937243T AT 97937243 T AT97937243 T AT 97937243T AT E253122 T1 ATE253122 T1 AT E253122T1
Authority
AT
Austria
Prior art keywords
target
vector
polynucleotide vector
vaccine vector
polynucleotide
Prior art date
Application number
AT97937243T
Other languages
English (en)
Inventor
Edward L Nelson
Peter J Nelson
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE253122T1 publication Critical patent/ATE253122T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97937243T 1996-08-14 1997-08-14 Vektor für polynukleotidimpfstoffe ATE253122T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2393196P 1996-08-14 1996-08-14
PCT/US1997/014306 WO1998006863A1 (en) 1996-08-14 1997-08-14 A vector for polynucleotide vaccines

Publications (1)

Publication Number Publication Date
ATE253122T1 true ATE253122T1 (de) 2003-11-15

Family

ID=21817994

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97937243T ATE253122T1 (de) 1996-08-14 1997-08-14 Vektor für polynukleotidimpfstoffe

Country Status (5)

Country Link
EP (1) EP0920522B1 (de)
AT (1) ATE253122T1 (de)
AU (1) AU3980497A (de)
DE (1) DE69725857T2 (de)
WO (1) WO1998006863A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054839A2 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
US8668905B2 (en) 2005-05-12 2014-03-11 University Of South Florida P53 vaccines for the treatment of cancers
CN101998965B (zh) 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
AU2011268934B2 (en) 2010-06-25 2015-09-10 Nykode Therapeutics ASA Homodimeric protein constructs
WO2013041966A1 (en) 2011-09-23 2013-03-28 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
AU2017205270B2 (en) 2016-01-08 2024-01-18 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
RU2734726C1 (ru) * 2020-01-15 2020-10-22 Генетик Диагностикс Энд Терапи 21 Лтд Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, несущий целевой ген, выбранный из группы генов DDC, IL10, IL13, IFNB1, TNFRSF4, TNFSF10, BCL2, HGF, IL2 для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli JM110-NAS/GDTT1.8NAS12-DDC, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL10, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL13, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNB1, или Escherichia coli JM110-NAS/GDTT1.8NAS12-TNFRSF4, или Escherichia coli JM110-NAS/GDTT1.8NAS12-TNFSF10, или Escherichia coli JM110-NAS/GDTT1.8NAS12-BCL2, или Escherichia coli JM110-NAS/GDTT1.8NAS12-HGF, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL2, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0538300T3 (da) * 1990-07-10 1994-10-10 Boehringer Ingelheim Int O-Glycosyleret IFN-alfa
US5128106A (en) * 1990-07-12 1992-07-07 Gte Products Corporation Lamp with an oxygen detector
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5426039A (en) * 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol

Also Published As

Publication number Publication date
EP0920522A1 (de) 1999-06-09
DE69725857T2 (de) 2004-07-29
DE69725857D1 (de) 2003-12-04
AU3980497A (en) 1998-03-06
EP0920522B1 (de) 2003-10-29
WO1998006863A1 (en) 1998-02-19

Similar Documents

Publication Publication Date Title
ATE230437T1 (de) Reagenzien zur impfung, die eine cd8 t-zell- immunantwort erzeugen
CY1123912T1 (el) Χρηση πonτικου που παραγει υβριδικα αντισωματα που περιεχουν ανθρωπινες μεταβλητες περιοχες και σταθερες περιοχες ποντικου ως πηγη dna που κωδικοποιει μια ανθρωπινη μεταβλητη περιοχη του εν λογω αντισωματος
IL74986A (en) Detecting target genetic material with desired base sequence or gene by using double labelled single-stranded polynucleotide sequences to form double-or multi-hybrid
MX9703606A (es) Vacuna de polinucleotido contra tuberculosis.
DK0465560T3 (da) Vacciner indeholdende avirulente mikroorganismer af phoP-type
DK0680513T3 (da) Målretning af immunogener med lysosomer
DK1152012T3 (da) Tuberkulosevacciner
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
ATE253122T1 (de) Vektor für polynukleotidimpfstoffe
DE69229476D1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
PT983370E (pt) Silenciamento de genes
KR880011342A (ko) 비a 비b형 간염 특이 항원을 코딩하는 dna 단편, 이 dna 단편을 함유하는 발현 벡터, 형질전환체 및 이 항원의 제조방법
WO1997026910A3 (de) Tumorimpfstoff für die immuntherapie von malignen tumoren
EP1135482A4 (de) Krebszellen-impfstoff
GB9922361D0 (en) Generating an immune response to an antigen
WO2003072789A3 (de) Mikroorganismen als träger von nukleotidsequenzen kodierend für zellantigene zur behandlung von tumoren
ATE442858T1 (de) Nukleinsäureadjuvantien
SE8604636D0 (sv) Sett att uttrycka gener med hjelp av bacillus brevis
AU1853995A (en) Vaccine compositions
MXPA01011563A (es) Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados.
Friedrich et al. A land great and rich in search of order.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties